PDF(Pubmed)
Abstract：
The coming of age for cancer treatment has experienced exponential growth in the last decade with the addition of immunotherapy as the fourth pillar to the fundamentals of cancer treatment-chemotherapy, surgery, and radiation-taking oncology to an astounding new frontier. In this time, rapid developments in computational biology coupled with immunology have led to the exploration of priming the host immune system through vaccination to prevent and treat certain subsets of cancer such as melanoma and hereditary colorectal cancer. By targeting the immune system through tumor-specific antigens-namely, neoantigens (neoAgs)-the future of cancer prevention may lie within arm\'s reach by employing neoAg vaccines as an immune-preventive modality for hereditary cancer syndromes like Lynch syndrome. In this review, we discuss the history, current trends, utilization, and future direction of neoAg-based vaccines in the setting of hereditary colorectal cancer.
摘要：
在过去的十年中，随着免疫疗法作为癌症治疗基础的第四支柱-化疗，癌症治疗的年龄的到来经历了指数增长。手术,和放射肿瘤学到一个惊人的新领域。在这个时候,计算生物学与免疫学的快速发展导致探索通过疫苗接种来启动宿主免疫系统，以预防和治疗某些癌症亚群，例如黑色素瘤和遗传性结直肠癌。通过肿瘤特异性抗原靶向免疫系统-即，新抗原（neoAg）-通过采用neoAg疫苗作为遗传性癌症综合征如Lynch综合征的免疫预防方式，癌症预防的未来可能在力所能及的范围内。在这次审查中,我们讨论历史，当前趋势,利用率，以及基于新Ag的疫苗在遗传性结直肠癌中的未来方向。
